{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:07:41Z","timestamp":1778054861380,"version":"3.51.4"},"reference-count":138,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.idc.2005.05.006","type":"journal-article","created":{"date-parts":[[2005,8,14]],"date-time":"2005-08-14T11:35:40Z","timestamp":1124019340000},"page":"713-729","source":"Crossref","is-referenced-by-count":26,"title":["Antiretroviral Therapy in HIV-Infected Children: The Metabolic Cost of Improved Survival"],"prefix":"10.1016","volume":"19","author":[{"given":"Ethan G.","family":"Leonard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace A.","family":"McComsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2005.05.006_bib1","unstructured":"Report on the global AIDS epidemic Geneva: Joint United Nations Programme on HIV\/AIDS; 2004."},{"key":"10.1016\/j.idc.2005.05.006_bib2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2005.05.006_bib3","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa011157","article-title":"Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1","volume":"345","author":"Gortmaker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2005.05.006_bib4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1086\/423178","article-title":"Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy","volume":"39","author":"Viani","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib5","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1086\/420738","article-title":"Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-infected children","volume":"38","author":"Resino","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00006454-200301000-00018","article-title":"Metabolic complications of antiretroviral therapy in children","volume":"22","author":"Leonard","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.006_bib7","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1097\/00002030-200409030-00004","article-title":"Metabolic complications of HIV therapy in children","volume":"18","author":"McComsey","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib8","unstructured":"Kingsley L, Smit E, Riddler S. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS). Presented at 8th Conference on Retroviruses and Opportunistic Infections. Chicago, 2001."},{"key":"10.1016\/j.idc.2005.05.006_bib9","unstructured":"Gripshover B, Tien PC, Saag M, et al. Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected men. Presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, 2003."},{"key":"10.1016\/j.idc.2005.05.006_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00006454-200205000-00011","article-title":"Lipodystrophy syndrome in human immunodeficiency virus-infected children","volume":"21","author":"Amaya","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.006_bib11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/00002030-200306130-00006","article-title":"Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children","volume":"17","author":"Bitnun","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.inf.0000068209.03069.2e","article-title":"Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors","volume":"22","author":"Bockhorst","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.006_bib13","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1097\/00002030-200112070-00009","article-title":"Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy","volume":"15","author":"Brambilla","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib14","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1097\/00002030-200009290-00008","article-title":"Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children","volume":"14","author":"Jaquet","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib15","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/00126334-200304150-00003","article-title":"Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children","volume":"32","author":"Vigano","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib16","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1592\/phco.21.9.861.34555","article-title":"Lipodystrophy syndrome in children infected with human immunodeficiency virus","volume":"21","author":"Wedekind","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.idc.2005.05.006_bib17","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib18","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","article-title":"A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00126334-200201010-00003","article-title":"Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors","volume":"29","author":"Galli","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","article-title":"Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection","volume":"14","author":"Mallal","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib21","unstructured":"Cohen C, Shen Y, Rode R, et al. Effect of nucleoside intensification on prevalence of morphologic abnormalities at year 5 of ritonavir plus saquinavir therapy in an HIV-infected cohort. Presented at 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002."},{"key":"10.1016\/j.idc.2005.05.006_bib22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/00002030-200105040-00005","article-title":"Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection","volume":"15","author":"van der Valk","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/135965350300800412","article-title":"Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy","volume":"8","author":"Galli","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1016\/j.idc.2005.05.006_bib24","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-200212060-00010","article-title":"Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial","volume":"16","author":"Joly","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib25","unstructured":"Podzamczer D, Ferrer E, Sanchez P, et al. Toxicity and efficacy of 3TC\/EFV associated with stavudine or abacavir in antiretroviral-naive patients: 48 week results of a randomized open and multicenter trial (ABCDE) study. Presented at 11th Conference on Retroviruses and Opportunistic Infections, San Francisco."},{"key":"10.1016\/j.idc.2005.05.006_bib26","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1086\/338811","article-title":"Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients","volume":"34","author":"Chene","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1310\/K2U9-QC2V-1Y3V-5DYF","article-title":"Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2","volume":"4","author":"Amin","year":"2003","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.idc.2005.05.006_bib28","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1542\/peds.111.3.e275","article-title":"Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study","volume":"111","author":"McComsey","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.idc.2005.05.006_bib29","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/317426","article-title":"Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy","volume":"31","author":"Martinez","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00126334-200305010-00004","article-title":"A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy","volume":"33","author":"Moyle","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00042560-200107010-00003","article-title":"Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study","volume":"27","author":"Ruiz","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib32","unstructured":"Boyd M, Bien D, Van Warmerdam P, et al. Lipodystrophy in patients switched to indinavir\/ritonavir 800\/100 mg BID and efavirenz 600 mg QD after failing nucleoside combination therapy: a prospective, 48-week observational sub-study of HIV-NAT. Presented at 10th Conference on Retrovirused and Opportunistic Infections. Boston, 2003."},{"key":"10.1016\/j.idc.2005.05.006_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","article-title":"Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study","volume":"38","author":"McComsey","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.idc.2005.05.006_bib35","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1056\/NEJM199604113341504","article-title":"Hyperinsulinemia as an independent risk factor for ischemic heart disease","volume":"334","author":"Despres","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2005.05.006_bib36","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1056\/NEJM199003293221303","article-title":"A prospective study of obesity and risk of coronary heart disease in women","volume":"322","author":"Manson","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2005.05.006_bib37","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1136\/bmj.288.6428.1401","article-title":"Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913","volume":"288","author":"Larsson","year":"1984","journal-title":"BMJ (Clin Res Educ)"},{"key":"10.1016\/j.idc.2005.05.006_bib38","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1047-2797(98)00002-7","article-title":"Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the \u201cminimal model.\u201d Insulin Resistance Atherosclerosis Study (IRAS) investigators","volume":"8","author":"Howard","year":"1998","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.idc.2005.05.006_bib39","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.2337\/diacare.19.10.1138","article-title":"A prospective analysis of the HOMA model. The Mexico City Diabetes Study","volume":"19","author":"Haffner","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.idc.2005.05.006_bib40","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2337\/diabetes.46.10.1594","article-title":"Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study","volume":"46","author":"Meigs","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.idc.2005.05.006_bib41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0002-9343(99)80220-4","article-title":"Body fat distribution, rather than overall adiposity, influences serum lipids and lipoproteins in healthy men independently of age","volume":"99","author":"Walton","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.idc.2005.05.006_bib42","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/368185","article-title":"Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution","volume":"36","author":"Hadigan","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib43","first-page":"795","article-title":"Peripheral and abdominal adiposity in childhood obesity","volume":"18","author":"Brambilla","year":"1994","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.idc.2005.05.006_bib44","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM199806043382302","article-title":"Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study","volume":"338","author":"Berenson","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2005.05.006_bib45","doi-asserted-by":"crossref","first-page":"149S","DOI":"10.1093\/ajcn\/70.1.149s","article-title":"Relation between visceral fat and disease risk in children and adolescents","volume":"70","author":"Goran","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.idc.2005.05.006_bib46","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.CIR.0000060923.07573.F2","volume":"107","author":"Steinberger","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.idc.2005.05.006_bib47","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMoa022048","article-title":"Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection","volume":"348","author":"Bozzette","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2005.05.006_bib48","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"Friis-Moller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2005.05.006_bib49","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients\u2013association with antiretroviral therapy. Results from the DAD study","volume":"17","author":"Friis-Moller","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib50","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/00002030-200311210-00010","article-title":"Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men","volume":"17","author":"Mary-Krause","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib51","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1097\/00002030-200112070-00012","article-title":"Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy","volume":"15","author":"Duran","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib52","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/00002030-200104130-00025","article-title":"The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men","volume":"15","author":"Dukers","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00126334-200309010-00006","article-title":"Lipid oxidative markers are significantly increased in lipoatrophy, but not in sustained asymptomatic hyperlactatemia","volume":"34","author":"McComsey","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib54","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00126334-200308150-00009","article-title":"Effects of antioxidants on plasma lipids and peripheral fat in HIV-infected subjects with lipoatrophy","volume":"33","author":"McComsey","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00126334-200210010-00006","article-title":"Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study","volume":"31","author":"Gelato","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib56","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial","volume":"140","author":"Hadigan","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2005.05.006_bib57","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(04)15489-5","article-title":"No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial","volume":"363","author":"Carr","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2005.05.006_bib58","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/135965350300800303","article-title":"Rosiglitazone in the treatment of HAART associated lipodystrophy: a randomized double-blind, placebo-controlled study","volume":"8","author":"Sutinen","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1016\/j.idc.2005.05.006_bib59","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1210\/jc.86.2.504","article-title":"Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy","volume":"86","author":"Rietschel","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.idc.2005.05.006_bib60","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00002030-200307040-00003","article-title":"Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents","volume":"17","author":"Vigano","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib61","unstructured":"Kotler DP, Grunfeld C, Muurahainen N, et al. Low-dose maintenance therapy with recombinant human growth hormone sustains effects of previous r-hGH treatment in HIV+patients with excess center fat: treatment results at 60 weeks. Presented at 11th Conference on Retroviruses and Opportunistic Infections. San Francisco."},{"key":"10.1016\/j.idc.2005.05.006_bib62","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00042560-200208010-00002","article-title":"Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection","volume":"30","author":"Engelson","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0002-9343(89)90225-8","article-title":"Hypertriglyceridemia in the acquired immunodeficiency syndrome","volume":"86","author":"Grunfeld","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.idc.2005.05.006_bib64","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1086\/317477","article-title":"Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine","volume":"31","author":"Thiebaut","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib65","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2005.05.006_bib66","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/archinte.160.13.2050","article-title":"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study","volume":"160","author":"Tsiodras","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.idc.2005.05.006_bib67","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1097\/00002030-199907300-00004","article-title":"Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome","volume":"13","author":"Wanke","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib68","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00042560-200001010-00005","article-title":"Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection","volume":"23","author":"Mulligan","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib69","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/00002030-200105040-00001","article-title":"Metabolic effects of indinavir in healthy HIV-seronegative men","volume":"15","author":"Noor","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00002030-200001070-00006","article-title":"Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects","volume":"14","author":"Purnell","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib71","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00042560-200105010-00005","article-title":"Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine","volume":"27","author":"Arpadi","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib72","unstructured":"Farley J, Gona P, Crain M, Cervia J, Lindsey J, Oleske J. Prevalence of hypercholesterolemia and associated risk factors among perinatally HIV-infected children (4\u201319 years) in PACTG 219C. Presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, 2003."},{"key":"10.1016\/j.idc.2005.05.006_bib73","unstructured":"Ramos J, Garcia L, Rojo P, et al. High prevalence of metabolic abnormalities in HIV infected children treated with HAART. Presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, 2003."},{"key":"10.1016\/j.idc.2005.05.006_bib74","unstructured":"Gunter E, Lewis B, Koncikowski S. Laboratory procedures used for the third National Health and Nutrition Examination Survey (NHANES III), 1988\u20131994. Hyatsville (MD): US Department of Health and Human Services. National Center for Health Statistics. 1996. p. VIIQ1\u2013VIIQ20."},{"key":"10.1016\/j.idc.2005.05.006_bib75","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1542\/peds.101.3.335","article-title":"A phase I\/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection","volume":"101","author":"Mueller","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.idc.2005.05.006_bib76","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/00002030-199909100-00008","article-title":"Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children","volume":"13","author":"Funk","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib77","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00126334-200207010-00004","article-title":"Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases","volume":"30","author":"Cheseaux","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib78","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","volume":"37","author":"Dube","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib79","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.idc.2005.05.006_bib80","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/S0140-6736(05)79858-5","article-title":"Lipid lowering therapy in patients with HIV infection","volume":"352","author":"Wierzbicki","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2005.05.006_bib81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00129784-200202020-00003","article-title":"Management of protease inhibitor-associated hyperlipidemia","volume":"2","author":"Penzak","year":"2002","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.idc.2005.05.006_bib82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.281.2.137","article-title":"Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial","volume":"281","author":"Stein","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.idc.2005.05.006_bib83","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1542\/peds.101.1.141","article-title":"Cholesterol in childhood","volume":"101","author":"American Academy of Pediatrics Committee on Nutrition","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.idc.2005.05.006_bib84","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/00002030-199905070-00009","article-title":"Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine","volume":"13","author":"Martinez","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib85","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/00002030-200207050-00010","article-title":"Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine","volume":"16","author":"Negredo","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib86","author":"Protease inhibitors may increase blood glucose in hiv patients","year":"1997"},{"key":"10.1016\/j.idc.2005.05.006_bib87","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/aje\/142.7.724","article-title":"Exploration of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance (FSIGT) tests. The Insulin Resistance Atherosclerosis Study","volume":"142","author":"Anderson","year":"1995","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.idc.2005.05.006_bib88","doi-asserted-by":"crossref","first-page":"F167","DOI":"10.1097\/00002030-199815000-00001","article-title":"Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients","volume":"12","author":"Walli","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib89","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-199907090-00001","article-title":"Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors","volume":"13","author":"Behrens","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib90","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00002030-200204120-00005","article-title":"Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations","volume":"16","author":"Murata","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib91","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2337\/diabetes.50.6.1425","article-title":"The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3\u2013L1 adipocytes","volume":"50","author":"Rudich","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.idc.2005.05.006_bib92","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1053\/meta.2002.34704","article-title":"Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy","volume":"51","author":"Hadigan","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.idc.2005.05.006_bib93","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1086\/317541","article-title":"Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy","volume":"32","author":"Hadigan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib94","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/00002030-200110190-00012","article-title":"Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome","volume":"15","author":"Kosmiski","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib95","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/ajcn\/76.2.460","article-title":"Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men","volume":"76","author":"Meininger","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.idc.2005.05.006_bib96","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1210\/jc.77.3.725","article-title":"Effects of maturational stage on insulin sensitivity during puberty","volume":"77","author":"Cook","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.idc.2005.05.006_bib97","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1210\/jc.80.1.172","article-title":"Gender and Tanner stage differences in body composition and insulin sensitivity in early pubertal children","volume":"80","author":"Travers","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.idc.2005.05.006_bib98","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/322680","article-title":"Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution","volume":"33","author":"Hadigan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib99","first-page":"397","article-title":"Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and\/or dyslipidemia","volume":"28","author":"Thoni","year":"2002","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.idc.2005.05.006_bib100","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1210\/jc.2002-020709","article-title":"Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance","volume":"87","author":"Hadigan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.idc.2005.05.006_bib101","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.284.4.472","article-title":"Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial","volume":"284","author":"Hadigan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.idc.2005.05.006_bib102","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00002030-199905280-00023","article-title":"Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib103","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJM199803263381303","article-title":"Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus","volume":"338","author":"Inzucchi","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2005.05.006_bib104","doi-asserted-by":"crossref","first-page":"176","DOI":"10.7326\/0003-4819-128-3-199802010-00002","article-title":"Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial","volume":"128","author":"Maggs","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2005.05.006_bib105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7326\/0003-4819-137-1-200207020-00008","article-title":"High prevalence of osteonecrosis of the femoral head in HIV-infected adults","volume":"137","author":"Miller","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2005.05.006_bib106","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1542\/peds.109.5.e74","article-title":"Osteonecrosis of the hip (Legg-Calve-Perthes disease) in human immunodeficiency virus-infected children","volume":"109","author":"Gaughan","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.idc.2005.05.006_bib107","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00042560-200109010-00017","article-title":"Increasing incidence of avascular necrosis of the hip in HIV-infected patients","volume":"28","author":"Keruly","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib108","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1086\/322779","article-title":"Osteonecrosis in patients infected with human immunodeficiency virus: a case-control study","volume":"184","author":"Glesby","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib109","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/319745","article-title":"Avascular necrosis of bone in patients with human immunodeficiency virus infection: report of 6 cases and review of the literature","volume":"32","author":"Brown","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00002030-200101260-00022","article-title":"Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy","volume":"15","author":"Lawal","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib111","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/367569","article-title":"Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals","volume":"36","author":"Mondy","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2005.05.006_bib112","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/00002030-200309050-00010","article-title":"Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy","volume":"17","author":"Bruera","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib113","unstructured":"McGowan J, Cheng A, Coleman S, Johnson A, Genant H. Assessment of bone mineral density (BMD) in HIV-infected antiretroviral therapy naive subjects. Presented at 8th Conference on Retroviruses and Opportunistic Infections. Chicago, 2001."},{"key":"10.1016\/j.idc.2005.05.006_bib114","unstructured":"Ramos J, Rojo P, Ruano C, et al. Stability of osteopenia in HIV-infected children over time. Presented at 11th Conference on Retrovirus and Opportunistic Infections. San Francisco."},{"key":"10.1016\/j.idc.2005.05.006_bib115","unstructured":"McComsey G, Leonard E. The effect of calcium and vitamin D on bone mineral density in HIV-infected children with osteoporosis. Presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, 2003."},{"key":"10.1016\/j.idc.2005.05.006_bib116","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/8756-3282(89)90074-4","article-title":"Sex differences in age-related loss of vertebral trabecular bone mass and structure\u2013biomechanical consequences","volume":"10","author":"Mosekilde","year":"1989","journal-title":"Bone"},{"key":"10.1016\/j.idc.2005.05.006_bib117","unstructured":"Lawal A, Engelson E, Wang J, Heymsefield S, Kotler D. Effect of oxandrolone upon bone mineral content in malnourished HIV+patients. Presented at 8th Conference on Retroviruses and Opportunistic Infections. Chicago, 2001."},{"key":"10.1016\/j.idc.2005.05.006_bib118","unstructured":"Lawal A, Engelson E, Wang J, Heymsfield SB, Kotler D. Effect of growth hormone on osteopenia in HIV+patients. Presented at 8th Conference on Retroviruses and Opportunistic Infections. Chicago, 2001."},{"key":"10.1016\/j.idc.2005.05.006_bib119","unstructured":"Mondy K, Powderly WG, Claxton S, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia\/osteoporosis associated with HIV infection. Presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, 2003."},{"key":"10.1016\/j.idc.2005.05.006_bib120","unstructured":"Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone turnover in HIV-associated osteopenia and osteoporosis. Presented at 11th Conference on Retrovirus and Opportunistic Infections. San Francisco."},{"key":"10.1016\/j.idc.2005.05.006_bib121","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-118-1-199301010-00007","article-title":"Lactic acidosis complicating the acquired immunodeficiency syndrome","volume":"118","author":"Chattha","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2005.05.006_bib122","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00002030-199303000-00012","article-title":"Hepatomegaly with severe steatosis in HIV-seropositive patients","volume":"7","author":"Freiman","year":"1993","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib123","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1097\/00002030-200012010-00012","article-title":"Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy","volume":"14","author":"Gerard","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib124","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0168-8278(99)80020-8","article-title":"Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion","volume":"30","author":"Chariot","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.idc.2005.05.006_bib125","first-page":"1433","article-title":"Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy","volume":"90","author":"Fortgang","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.idc.2005.05.006_bib126","first-page":"611","article-title":"Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases","volume":"11","author":"ter Hofstede","year":"2000","journal-title":"Int J Sex Transm Dis AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib127","unstructured":"Lonergan JT, Havlir D, Barber E, Matthews WC. Incidence and outcome of hyperlactatemia associated with clinical manifestations in HIV-infected adults receiving NRTI-containing regimens. Presented at 8th Conference on Retroviruses and Opportunistic Infections. Chicago, 2001."},{"key":"10.1016\/j.idc.2005.05.006_bib128","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0140-6736(99)07219-0","article-title":"Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues","volume":"354","author":"Blanche","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2005.05.006_bib129","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1097\/00002030-200308150-00006","article-title":"Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort","volume":"17","author":"Barret","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib130","unstructured":"Gianquinto C, Rampon O, Torresan S, et al. Lactic acid levels in infants exposed to ART during fetal life. Presented at 11th Conference on Retroviruses and Opportunistic Infections. San Francisco."},{"key":"10.1016\/j.idc.2005.05.006_bib131","unstructured":"Alimenti A, Ogilvie G, Burdge D, Money D, Forbes J. Lactic acidemia in infants exposed to perinatal antiretroviral therapy. Presented at 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002."},{"key":"10.1016\/j.idc.2005.05.006_bib132","unstructured":"Brinkman K, Troost N, Schrijnders L, et al. Usefulness of routine lactate measurement to prevent lactic acidosis: evaluation of a protocol. Presented at 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002."},{"key":"10.1016\/j.idc.2005.05.006_bib133","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/135965350400900210","article-title":"Asymptomatic hyperlactatemia: predictive value, natural history and correlates","volume":"9","author":"McComsey","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.idc.2005.05.006_bib134","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1097\/00002030-200307040-00020","article-title":"Lactate levels in children with HIV\/AIDS on highly active antiretroviral therapy","volume":"17","author":"Desai","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib135","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/01.inf.0000083826.11124.b1","article-title":"Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment","volume":"22","author":"Noguera","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.idc.2005.05.006_bib136","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1097\/00002030-200311210-00012","article-title":"Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis","volume":"17","author":"Lonergan","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.idc.2005.05.006_bib137","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/00126334-200408010-00007","article-title":"Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine","volume":"36","author":"Lonergan","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.idc.2005.05.006_bib138","unstructured":"Ribera E, Sauleda S, Paradineiro J, et al. Increase in mitochondrial DNA in PBMCs and improvement of lipid profile and lactate levels in patients with lipoatrophy when stavudine is switched to tenofovir. Presented at 9th European AIDS Conference. Warsaw, Poland, 2003."}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552005000425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552005000425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T01:25:00Z","timestamp":1706491500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552005000425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":138,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0891552005000425"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2005.05.006","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}